Growth delay due to insulin-like growth factor I resistance
MONDO:0010038Growth delay due to IGF-I resistance is characterized by variable intrauterine and postnatal growth retardation and elevated serum IGF-I levels. Addition features include variable degrees of intellectual deficit, microcephaly and dysmorphism (broad nasal bridge and tip, smooth philtrum, thin upper and everted lower lips, short fingers, clinodactyly, wide-set nipples and pectus excavatum).
Also known as: growth delay due to insulin-like growth factor I resistance, resistance to IGF-1, IGF-1 resistance, IGF-I resistance, IGF1RES, Somatomedin end-organ insensitivity to, Somatomedin, end-organ insensitivity to, Somatomedin-C, resistance to
4 clinical trials for this condition and its sub-types, 4 tagged with Growth delay due to insulin-like growth factor I resistance itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New antibody IBI311 takes on steroids in Head-to-Head trial for thyroid eye disease
Disease control Recruiting nowThis study tests whether a new drug called IBI311 works better than standard steroid therapy for people with active moderate to severe thyroid eye disease. 64 participants will receive either IBI311 or steroids, and researchers will measure improvements in eye bulging, inflammati…
Phase 4 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 26, 2026 13:13 UTC
-
New antibody drug aims to ease double vision and bulging eyes in thyroid disease
Disease control Recruiting nowThis study tests a drug called IBI311 in 50 people with inactive moderate-to-severe thyroid eye disease, a condition that can cause bulging eyes and double vision. IBI311 is an antibody that blocks a protein involved in the disease. The goal is to see if it improves eye symptoms …
Phase 4 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 26, 2026 13:04 UTC
-
New combo therapy aims to tame thyroid eye disease
Disease control Recruiting nowThis study tests a two-step treatment for people with moderate-to-severe thyroid eye disease (TAO) that is still active. First, patients receive high-dose steroids, then a newer drug called tetuzumab (IBI311) that blocks a growth factor receptor. The goal is to reduce bulging eye…
Phase 4 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 26, 2026 12:42 UTC